A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer.

ABSTRACT:

Context/objectives

Pazopanib, an inhibitor of kinases including vascular endothelial growth factor receptor, demonstrated impressive activity in progressive metastatic differentiated thyroid cancer, prompting its evaluation in anaplastic thyroid cancer (ATC).

Design/setting/patients/interventions/outcome measures

Preclinical studies, followed by a multicenter single arm phase 2 trial of continuously administered 800 mg pazopanib daily by mouth (designed to provide 90% chance of detecting a response rate of >20% at the 0.10 significance level when the true response rate is >5%), were undertaken. The primary trial end point was Response Evaluation Criteria in Solid Tumors (RECIST) response.

Results

Pazopanib displayed activity in the KTC2 ATC xenograft model, prompting

SUBMITTER: Bible KC 

PROVIDER: S-EPMC3431569 | biostudies-literature | 2012 Sep

REPOSITORIES: biostudies-literature